A phase I dose-finding and pharmacokinetic/pharmacodynamic study of pacritinib (SB1518) has shown safety and early clinical activity in patients with relapsed B-cell lymphoma, providing the first proof of principle of the potential clinical value of targeting JAK/STAT pathway in B-cell lymphoma [317, 321]. The gene discussed is SOAT1; the disease is B-cell non-Hodgkin lymphoma.